KPF
CLBT icon

K2 Principal Fund’s Cellebrite CLBT Stock Holding History

K2 Principal Fund’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-130,400
Closed -$1.21M – 379
2021
Q3 		$1.21M Buy
+130,400
New +$1.36M 0.1% 168

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return
IP
Isomer Partners New York $74.3M AUM 23.95% 1-Year Est. Return
CIBC Asset Management
CIBC Asset Management Toronto, Ontario, Canada $40.9B AUM 35.96% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.02B AUM 9.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
TAM
Telemark Asset Management Boston, Massachusetts $1.08B AUM 70.88% 1-Year Est. Return
CPM
Crescent Park Management East Palo Alto, California $29M AUM 1.79% 1-Year Est. Return
BCM
Bienville Capital Management New York $550M AUM 3.49% 1-Year Est. Return

K2 Principal Fund's CLBT Position: Q4 2021 in Review

K2 Principal Fund sold out of Cellebrite (CLBT) in Q4 2021, closing a stake of 47,901 shares — an estimated $444K sold.

K2 Principal Fund first reported a position in CLBT in Q3 2021 and held it in 1 quarter. The position peaked at $444K in Q3 2021. 48 funds tracked by Wall St. Rank hold CLBT as of Q4 2021.

  • K2 Principal Fund reported no remaining Cellebrite position as of Q4 2021 after selling out during the quarter.
  • K2 Principal Fund sold 47,901 Cellebrite shares in Q4 2021, an estimated $444K.
  • K2 Principal Fund first reported a position in Cellebrite in Q3 2021 and held it in 1 quarter.
  • K2 Principal Fund's Cellebrite position peaked at $444K in Q3 2021.
  • 48 funds tracked by Wall St. Rank held Cellebrite as of Q4 2021.

Based on K2 Principal Fund's 13F filing for Q4 2021, filed 11 Feb 2022.